As the biotech markets warm up, signs point to crossover rounds returning
Crossover rounds appear to be trickling back into biotech.
During the boom times of 2020 and 2021, there was a flood of money from public …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
